Lance Betson, DO
Urogynecology and Reconstructive Pelvic Surgery · Newport Beach, CANPI 1497834964
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (54.0%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Intuitive Surgical at 57.8% of the total. Reporting peaked in 2024 at $3,512 and has fallen 86.1% since, to $487 in 2025.
Across 169 payments — averaging $49.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Medtronic$1K
- AbbVie$707
- Boston Scientific$437
- Pfizer$262
- Astellas Pharma US Inc$197
- plus $910 from 18 others
What the payments were for
- Food & beverage$3,86946%
- Education$4,56254%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $4,881 |
| Medtronic(2 entities) | 40 | $1,051 |
| AbbVie(2 entities) | 31 | $707 |
| Boston Scientific | 5 | $437 |
| Pfizer | 14 | $262 |
| Astellas Pharma US Inc | 8 | $197 |
| Ascend Therapeutics US, LLC | 38 | $147 |
| Mayne Pharma Commercial LLC | 1 | $122 |
| Sumitomo Pharma America, Inc. | 1 | $122 |
| Urocure LLC | 1 | $99 |
| Coopersurgical, Inc. | 2 | $84 |
| Viiv Healthcare Company | 4 | $58 |
| Axonics, Inc. | 3 | $54 |
| Femselect Inc. | 1 | $36 |
| Caldera Medical, Inc | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| KARL Storz Endoscopy-america | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Tesaro, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Myovant Sciences Inc. | 1 | $18 |
| Channel Medsystems, Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$4,500
- Advantage System$272
- Da Vinci Surgical System$237
- INTERSTIM$147
- BIJUVA$122
- MYFEMBREE$122
How this compares
$8,446 in reported general payments places this provider in the 70th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 76 | $55,503 |
| GemtesaVibegron | 64 | $49,462 |
| PremarinEstrogens, Conjugated | 106 | $44,108 |
| EstringEstradiol | 35 | $18,050 |
| Estradiol | 132 | $7,769 |
| Estradiol (Twice Weekly)Estradiol | 86 | $6,709 |
| Vivelle-DotEstradiol | 14 | $4,691 |
| YuvafemEstradiol | 15 | $1,892 |
| Methenamine Hippurate | 17 | $1,675 |
| SynthroidLevothyroxine Sodium | 13 | $1,191 |
| ClimaraEstradiol | 13 | $972 |
| ProgesteroneProgesterone, Micronized | 37 | $794 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 35 | $554 |
| Solifenacin Succinate | 12 | $505 |
| NitrofurantoinNitrofurantoin Macrocrystal | 13 | $471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Estring | $262 | $62,159141 claims |
| Astellas Pharma US IncMyrbetriq | $197 | $55,50376 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $122 | $49,46264 claims |
| AbbVieSynthroid | $707 | $1,19113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Newport Beach
- Matthew ClarkNewport Beach$33K
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.